Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dogs 'improve wellbeing of cancer patients'
dog
"These new results help advance our understanding of the value of animal-assisted therapy in cancer treatment."
Clinical research underscores the benefits of therapy dogs

A new clinical study has found therapy dogs can improve the emotional wellbeing of some cancer patients, even when those patients are experiencing significant deterioration in their physical wellbeing.

Carrying out the first study of this kind, researchers from Mount Sinai Beth Israel studied the effect of certified therapy dogs on patients receiving multi-modal radiation therapy and chemotherapy for gastrointestinal, head and neck cancers.

According to the findings, published in the Journal of Community and Supportive Oncology, patients experienced significant improvements in emotional wellbeing, despite marked declines in their physical and functional wellbeing.

"This study is the first such definitive study in cancer," said Stewart Fleishman, founding director of Cancer Supportive Services at Mount Sinai Beth Israel.

"It shows the importance of an innovative environmental intervention during cancer treatment. Having an animal-assisted visit significantly improved their quality of life and 'humanised' a high-tech treatment."

Patients even said they would not have completed their treatments were it not for the presence of the therapy dog and volunteer handler, he added.

The research team studied 42 adult patients, 37 of which continued with the study for its entirety. Each received 15-20 minute animal-assisted visits each day.

The patients had aggressive cancers of the head and neck, and were undergoing rigorous chemotherapy and radiotherapy concurrently. They were extremely fatigued, frightened and losing weight that was essential for maintaining their strength. Many of the patients had feeding tubes, lots of mucus in the mouth and throat and temporary loss of their sense of smell and taste.

The patients' quality of life was assessed before, during and after the study using a test routinely used in clinical cancer trials. Researchers expected their emotional wellbeing to decline at a similar rate to their physical wellbeing, but in fact it increased.

J. Michael McFarland from Zoetis, who supported the study, said: "There is mounting evidence in human and veterinary medicine that the emotional bond between people and companion animals can have a positive impact of emotional and physical health.

"These new results help advance our understanding of the value of animal-assisted therapy in cancer treatment and point to the ways the oncology and animal health communities can work together in supporting cancer patients achieve the best possible treatment outcomes."

View the full research paper here: http://www.oncologypractice.com/fileadmin/content_pdf/aats/supplement_pdf/JCSO_Jan2015_digitaledition_lores.pdf

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.